Bisgin et al. BMC Cancer 2012, 12:58 http://www.biomedcentral.com/1471-2407/12/58 33. Granci V, Bibeau F, Kramar A, Boissière-Michot F, Thézénas S, Thirion A, Gongora C, Martineau P, Del Rio M, Ychou M: Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 2008, 44:2312-2318. 34. Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V, Coskun U, Yamac D, Sancak B, Uner A: The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol 2010, 136(10):1471-1476, Epub 2010 Feb 13. 35. Jubb AM, Harris AH: Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11:1172-1183. 36. Yang SX: Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009, 9(12):1715-1725. 37. Beatty GL, Giantonio BJ: Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Rev Anticancer Ther 2008, 8(5):683-688. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/12/58/prepub doi:10.1186/1471-2407-12-58 Cite this article as: Bisgin et al.: Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 2012 12:58. Page 5 of 5 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit